EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

Clinical outcome and genomic biomarkers of immune checkpoint inhibitor-based therapies for cancer of unknown primary: a multicenter, real-world study

Yunjie Huang, Riqing Huang, Meiting Chen, Zhousan Zheng, Haifeng Li, Rishang Chen, Tinghua Gao, Ditian Shu, Anqi Hu, Qiufan Zheng, Xin An, Yanxia Shi und 1 weitere

Journal of Cancer Research and Clinical Oncology · 2025

DOI: 10.1007/s00432-025-06261-3 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Journal of Cancer Research and Clinical Oncology, 2025. Verfasst von Yunjie Huang und 12 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer Center, Guan…. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Neoplasms, Unknown Primary, Biomarkers, Tumor, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key Research and Development Program of China, Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Given the limited treatment options recommended for cancer of unknown primary (CUP), especially the role of immune checkpoint inhibitors (ICIs), our study aimed to evaluate the efficacy of ICIs and identify associated genomic biomarkers in these patients.

Methods

This retrospective, multicenter, real-world analysis included individuals with oncologist-confirmed CUP cases treated with ICIs across four hospitals in China. Clinical outcomes, safety and biomarkers were analyzed.

Results

Between January 2016 and November 2023, 124 patients were enrolled. Of these, 117 patients underwent combination therapy, predominantly ICIs with taxane-platinum based chemotherapy (54.84%), while 7 received monotherapy. After a median follow-up of 18.6 months, the median progression free survival (PFS) and overall survival (OS) were 23.20 and 38.86 months, respectively. According to ESMO guideline, patients were stratified into favorable (n = 41) and unfavorable subset (n = 83). The favorable subset demonstrated significantly longer PFS and OS than the unfavorable subset (median PFS NR vs. 9.7 months, P < 0.001; median OS NR vs. 23.73 months, P < 0.001). There are 31 patients in our cohort whose PD-L1 detection results are available, while 25 patients was eligible for TMB assessment. Better clinical efficacy of ICIs was apparent for tumors with a higher PD-L1 expression (CPS ≥ 20) and a greater tumor mutation burden (> 12 mutations/Mb). Multivariate analyses revealed that higher ECOG performance status, the presence of visceral metastasis, and KRAS mutation were independently associated with inferior PFS and OS. Immune-related adverse events occurred in 49 (39.52%) patients, with one developing grade 3 pneumonia.

Conclusions

The application of ICIs showed encouraging efficacy with an acceptable safety profile, suggesting its potential as an additional therapeutic option for CUP patients. Identifying predictive markers for ICIs response remains essential to enhance therapeutic strategies in CUP management.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immune Checkpoint InhibitorsNeoplasms, Unknown PrimaryBiomarkers, TumorAntineoplastic Combined Chemotherapy ProtocolsHumansMaleFemaleMiddle AgedAgedRetrospective StudiesAdultAged, 80 and overTreatment OutcomeGenomics

Stichwörter der Autor:innen

Cancer of unknown primaryGenomic biomarkerImmune checkpoint inhibitorKRASProgrammed death-ligand 1 expression

Substanzen

Immune Checkpoint InhibitorsBiomarkers, Tumor

Autor:innen und Institutionen

  • State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, People's Republic of China.
  • Department of Medical Oncology, State Key Laboratory of Oncology in South China, Sun Yat-Sen University Cancer Center, Dongfeng Road East 651, Guangzhou, 510060, People's Republic of China.
  • Department of Oncology, The First Affiliated Hospital of Sun Yat-Sen University, No. 58, Zhongshan Road II, Guangzhou, 510080, People's Republic of China.
  • Medical Oncology Department III, Central Hospital of Guangdong Nongken, Zhanjiang, 524002, China.
  • Department of Oncology, The First People's Hospital of Zhaoqing City, Zhaoqing, Guangdong, China.
  • State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, People's Republic of China. shiyx@sysucc.org.cn.

Förderung

  • National Key Research and Development Program of China
  • Natural Science Foundation of China

Zitieren

APA

Huang, Y., Huang, R., Chen, M., Zheng, Z., Li, H., Chen, R., Gao, T., Shu, D., Hu, A., Zheng, Q., An, X., Shi, Y., & Xue, C. (2025). Clinical outcome and genomic biomarkers of immune checkpoint inhibitor-based therapies for cancer of unknown primary: a multicenter, real-world study. Journal of Cancer Research and Clinical Oncology. https://doi.org/10.1007/s00432-025-06261-3

Vancouver

Huang Y, Huang R, Chen M, Zheng Z, Li H, Chen R, et al. Clinical outcome and genomic biomarkers of immune checkpoint inhibitor-based therapies for cancer of unknown primary: a multicenter, real-world study. Journal of Cancer Research and Clinical Oncology. 2025. doi:10.1007/s00432-025-06261-3

BibTeX
@article{Huang2025,
  author = {Huang, Yunjie and Huang, Riqing and Chen, Meiting and Zheng, Zhousan and Li, Haifeng and Chen, Rishang and Gao, Tinghua and Shu, Ditian and Hu, Anqi and Zheng, Qiufan and An, Xin and Shi, Yanxia and Xue, Cong},
  title = {Clinical outcome and genomic biomarkers of immune checkpoint inhibitor-based therapies for cancer of unknown primary: a multicenter, real-world study},
  journal = {Journal of Cancer Research and Clinical Oncology},
  year = {2025},
  doi = {10.1007/s00432-025-06261-3}
}
Kostenlos starten →